ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 1785

Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis

(1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1748

Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1776

Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression

(1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2422

Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial)

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 2384

Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group

(2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

9:00AM-11:00AM: Abstract Number: 2059

Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 1927

Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review

(1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

9:00AM-11:00AM: Abstract Number: 1739

Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 2057

Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2299

Medication-related Hospitalizations in Systemic Lupus Erythematosus

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2093

Meeting the Educational and Language Needs of the Lupus Community: A Snapshot of 2022 Lupus Inquiries

(2089–2094) Patient Education/Community Service – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 2287

Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2268

Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1760

Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1789

Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion

(1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].